MIVetsCan: Cannabidiol (CBD)-Care Trial

Inclusion Criteria: * Ability to read and speak English sufficiently to allow for written informed consent and patient-reported outcomes measures * Armed Services Veteran * All participants must have been enrolled in the MIVetsCan Pain Registry (HUM00223894) for at least 4 weeks and agree to continue participation in that study. * Reports moderate to severe chronic pain defined by protocol * Currently using or interested in using cannabis for pain management * Self-reported willingness to refrain from or not increase current Tetrahydrocannabinol (THC) or other cannabis product use (including CBD) during the study intervention or other cannabinoid use during the study intervention * Individuals of reproductive potential must agree to use acceptable birth control per protocol * Participants must also agree not to donate sperm or eggs during study drug administration * Willingness to attend all study visits (may be done virtually) * Ability to take and to swallow the study medication and be willing to adhere to the treatment regimen * Willingness to wear Fitbit or other similar sensor for passive-data collection * Willingness to fill out daily diary via smartphone to assess symptom status, study drug use, and other cannabis use Exclusion Criteria: * Not an Armed Services Veteran * Inability to provide informed consent (e.g., cognitive impairment, unable to sufficiently communicate in English) * Participant reports pregnancy or are nursing * Planning to move out of a state with legal recreational marijuana use during course of study * Risk for imminent harm - Suicidal ideation or wish to die as assessed per protocol * Any impairment, activity, behavior, or situation that in the judgment of the study team would prevent satisfactory completion of the study protocol * Participation in any other clinical trials over the course of this study * Medical or psychiatric conditions that in the judgment of study personnel would preclude participation in this study (e.g., psychosis, suicidal ideation; note that stable anxiety and depression are not exclusions) * Having a serious or unstable hepatic disease (e.g., non-alcoholic fatty liver disease or liver cirrhosis) * Individuals with major neurological disorders, such as dementia, Parkinson's disease, cognitive impairment, epilepsy, and seizures * Recent/new diagnosis of cancer within the past 3 years (other than localized melanoma, localized basal cell carcinoma, localized squamous cell carcinoma treated or untreated) * Current valproate and clobazam use per self-report or medical records * Self-reported allergies to sesame oil or cannabis/cannabinoids